GlassScriptPhysician profile
Alfred Okeke
NPI 1093753436
$221,549.42
in general payments reported to CMS, 2019-2025
42 companies · $9,281 in 2025
The $9,281 reported for 2025 was more than what 90% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $33K · 2021: $35K · 2022: $51K · 2023: $12K · 2024: $16K · 2025: $9,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Travel and Lodging: $5,456 · Food and Beverage: $4,618 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,952.75 |
| Travel and Lodging | $5,456.25 |
| Food and Beverage | $4,618.35 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $138,405.79 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $43,022.69 | 2019-2025 | Farxiga, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $27,298.72 | 2021-2025 | |
| Mannkind Corporation | $5,078.92 | 2019-2025 | Afrezza |
| Janssen Pharmaceuticals, INC | $2,382.03 | 2019 | |
| Medtronic, INC. | $1,670.33 | 2023-2024 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $464.80 | 2019-2025 | |
| Medtronic Minimed, INC. | $395.10 | 2019-2020 | |
| Lilly USA, LLC | $266.05 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Zealand Pharma US, INC. | $263.79 | 2021-2022 | |
| Sequel Med Tech, LLC | $233.82 | 2025 | Twiist |
| Cequr Corporation | $209.55 | 2024-2025 | Cequr Simplicity |
| Lundbeck LLC | $200.66 | 2024-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $200.51 | 2024-2025 | Ultomiris |
| Aucta Pharmaceuticals, INC. | $165.99 | 2024-2025 | Motpoly Xr |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $138.44 | 2025 | Korlym |
| Neurocrine Biosciences, INC. | $122.50 | 2024-2025 | Ingrezza |
| Neurelis, INC. | $116.19 | 2024-2025 | Valtoco |
| Beta Bionics, INC. | $89.08 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Recordati_rare_diseases_inc. | $80.61 | 2024-2025 | Isturisa, Signifor Lar |
| Shire North American Group INC | $63.10 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.06 | 2019-2025 | Jardiance |
| Ucb, INC. | $55.14 | 2024-2025 | Nayzilam |
| Radius Health, INC. | $49.54 | 2024 | Tymlos |
| Merck Sharp & Dohme LLC | $47.46 | 2024 | Keytruda, Zerbaxa, Dificid |
| Regeneron Healthcare Solutions, INC. | $43.79 | 2025 | Dupixent |
| Ascendis Pharma Endocrinology INC | $41.80 | 2025 | Yorvipath |
| Amgen INC. | $38.06 | 2025 | Tepezza |
| Xeris Pharmaceuticals, INC. | $32.89 | 2022 | |
| Averitas Pharma INC. | $31.66 | 2024 | Qutenza |
| Abbvie INC. | $31.51 | 2024-2025 | |
| Glaxosmithkline, LLC. | $30.46 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Verona Pharma, INC. | $28.63 | 2025 | Ohtuvayre |
| Tg Therapeutics, INC. | $27.33 | 2025 | |
| Inogen, INC. | $25.67 | 2025 | |
| Abbott Laboratories | $23.67 | 2025 | Freestyle Libre 2 |
| Insulet Corporation | $23.52 | 2024 | Omnipod |
| Emd Serono, INC. | $23.25 | 2025 | |
| Grifols USA, LLC | $20.96 | 2025 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $18.13 | 2024 | Inspire |
| Otsuka America Pharmaceutical, INC. | $16.63 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $14.59 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Okeke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.